India’s opportunity to build preventive healthcare economy

The country’s strength lies not just in technology availability but in adoption behaviour

Aarti Drugs posts steady FY26 growth & sharp Q4 rebound despite margin pressure

KIMS Hospitals posts strong revenue growth but profits slip sharply in FY26

Profit after tax took a sharp hit, falling to Rs. 33 Cr in Q4 FY26, down from Rs. 106 Cr in Q4 FY25 and Rs. 52 Cr in Q3 FY26

Cupid shatters FY26 guidance with record 93% revenue jump & 165% profit surge

Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels

SN Bioscience doses first patient in global trial of experimental drug for aggressive lung cancer

The drug also delivered a disease control rate (DCR) of 83.3% in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients

Alivus Life Sciences posts steady FY26 growth as margins surge past guidance

The company reported free cash flow of Rs. 2,590 Mn for FY26

OrganaBio expands cell therapy manufacturing footprint with acquisition of Excellos Assets

The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego

Dyno unveils next-gen AI-designed gene delivery capsids targeting brain & muscle

This positions its platform as a rapidly evolving engine for next-generation genetic medicine

Lupin debuts in Dow Jones best-in-class indices for ESG performance

The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index

Roche Pharma launches India’s first subcutaneous immunotherapy for lung cancer

Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs